EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?

Caroline Lonez iD, Eytan Breman iD

Cells · 12.01.2024 · 13 (2) · 146

DOI: 10.3390/cells13020146 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 12.01.2024. Verfasst von Caroline Lonez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Celyad Oncology SA, 1435 Mont-Saint-Guibert, Belgium. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 115-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real treatment option for patients with B-cell malignancies, while multiple efforts are being made to extend this therapy to other malignancies and broader patient populations. However, several limitations remain, including those associated with the time-consuming and highly personalized manufacturing of autologous CAR-Ts. Technologies to establish “off-the-shelf” allogeneic CAR-Ts with low alloreactivity are currently being developed, with a strong focus on gene-editing technologies. Although these technologies have many advantages, they have also strong limitations, including double-strand breaks in the DNA with multiple associated safety risks as well as the lack of modulation. As an alternative, non-gene-editing technologies provide an interesting approach to support the development of allogeneic CAR-Ts in the future, with possibilities of fine-tuning gene expression and easy development. Here, we will review the different ways allogeneic CAR-Ts can be manufactured and discuss which technologies are currently used. The biggest hurdles for successful therapy of allogeneic CAR-Ts will be summarized, and finally, an overview of the current clinical evidence for allogeneic CAR-Ts in comparison to its autologous counterpart will be given.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHematopoietic Stem Cell TransplantationHumansGene EditingImmunotherapy, Adoptive

Stichwörter der Autor:innen

allogeneicchimeric antigen receptorgene editingoff-the-shelf

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Celyad Oncology SA, 1435 Mont-Saint-Guibert, Belgium.

ORCID-Profile: Caroline Lonez, Eytan Breman

Zitieren

APA

Lonez, C., & Breman, E. (2024). Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells, 13(2), 146. https://doi.org/10.3390/cells13020146

Vancouver

Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells. 2024;13(2):146. doi:10.3390/cells13020146

BibTeX
@article{Lonez2024,
  author = {Lonez, Caroline and Breman, Eytan},
  title = {Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {2},
  pages = {146},
  doi = {10.3390/cells13020146}
}
Kostenlos starten →